PDF下载 ( 4588 KB)
环状RNA hsa_circ_0091579对肝癌细胞增殖、迁移和侵袭的影响
DOI: 10.3969/j.issn.1001-5256.2021.05.029
利益冲突声明本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明：于维凯、冯婷婷、冯万文负责课题设计，资料分析，撰写论文；陈晓兵、骆继业参与收集数据，修改论文；于维凯、王言理负责拟定写作思路，指导撰写文章并最后定稿。
Effect of circRNA hsa_circ_0091579 on the proliferation, migration, and invasion of hepatoma cells
-
摘要:
目的 探究环状RNA(circRNA)hsa_circ_0091579在肝细胞癌(HCC)细胞系中的表达及其对HCC细胞增殖、迁移和侵袭的影响。 方法 体外培养人肝癌细胞系SMMC-7721、HuH-7、MHCC-97H、HepG2和人正常肝细胞系HL-7702。从细胞中提取RNA，用实时荧光定量PCR(qRT-PCR)检测hsa_circ_0091579在HCC细胞系及人正常肝细胞系中的表达，并进行对比。针对hsa_circ_0091579的环化拼接位点设计siRNA，在体外HepG2和HuH-7细胞中转染hsa_circ_0091579 siRNA，并用qRT-PCR验证其有效性。实验分为siRNA组(hsa_circ_0091579 siRNA)和NC组(negative control siRNA)，并在HepG2和HuH-7细胞中用CCK8实验、流式细胞术、划痕实验以及Transwell实验分别研究hsa_circ_0091579对细胞增殖、凋亡、迁移和侵袭的影响。使用双荧光素酶报告基因实验对预测的靶点进行验证。计量资料两组间比较采用t检验。 结果 与hsa_circ_0091579在人正常肝细胞系HL-7702中的表达水平相比，其在HCC细胞系SMMC-7721、HuH-7、MHCC-97H、HepG2中的表达水平均明显升高(t值分别为14.27、36.34、26.70、36.16，P值均 < 0.001)。与NC组相比，hsa_circ_0091579 siRNA可在HepG2和HuH-7细胞中有效沉默hsa_circ_0091579(t值分别为14.22、27.20，P值分别为0.005、0.001)。CCK8实验和流式细胞术结果显示，与NC组相比，siRNA组HepG2和HuH-7细胞的增殖活性明显降低，凋亡率明显升高，差异均有统计学意义(P值均 < 0.05)；划痕实验和Transwell实验显示，与NC组相比，siRNA组HepG2和HuH-7细胞的迁移和侵袭能力明显减弱(t值分别为19.63、13.61、20.75、18.45，P值分别为0.003、0.005、0.002、0.003)。荧光素酶报告基因实验结果显示，与NC组相比，miR-149、miR-490-5p和miR-502-5p均能明显降低野生型荧光素酶质粒的活性(t值分别为10.01、9.13、61.49，P值分别为0.010、0.012、 < 0.001)。 结论 hsa_circ_0091579在HCC细胞系中高表达，可能通过抑制miR-149、miR-490-5p和miR-502-5p发挥其癌基因的作用。 Abstract:Objective To investigate the expression of circular RNA (cirRNA) hsa_circ_0091579 in human hepatocellular carcinoma (HCC) cell lines and its effect on the proliferation, migration, and invasion of HCC cells. Methods Human HCC cell lines SMMC-7721, Huh-7, MHCC-97H, and HepG2 and normal human liver cell line HL-7702 were cultured in vitro. RNA was extracted from cells and quantitative real-time PCR (qRT-PCR) was used to measure the expression of hsa_circ_0091579 in HCC cell lines and normal human liver cell line. Small interfering RNA (siRNA) was designed for the cyclic splicing site of hsa_circ_0091579, and HepG2 and Huh-7 cells were transfected with hsa_circ_0091579 siRNA in vitro; qRT-PCR was used to verify transfection efficiency. The experiment was divided into siRNA group (transfected with hsa_circ_0091579 siRNA) and NC group (transfected with negative control siRNA), and CCK-8 assay, flow cytometry, wound healing assay, and Transwell assay were used to investigate the effect of hsa_circ_0091579 on cell proliferation, apoptosis, migration, and invasion in HepG2 and Huh-7 cells. Dual luciferase reporter gene assay was used to verify the predicted target. The t-test was used for comparison of continuous data between the two groups. Results Compared with the normal human liver cell line HL-7702, the HCC cell lines SMMC-7721, Huh-7, MHCC-97H, and HepG2 had a significant increase in the expression level of hsa_circ_0091579 (t=14.27, 36.34, 26.70, and 36.16, all P < 0.001). Compared with the NC group, hsa_circ_0091579 siRNA effectively silenced hsa_circ_0091579 in HepG2 and Huh-7 cells (t=14.22 and 27.20, P=0.005 and 0.001). CCK-8 assay and flow cytometry showed that compared with the NC group, the siRNA group had a significant reduction in the proliferative activity of HepG2 and Huh-7 cells and a significant increase in apoptosis rate (all P < 0.05); wound healing assay and Transwell assay showed that compared with the NC group, the siRNA group had significant reductions in the migration and invasion abilities of HepG2 and Huh-7 cells (t=19.63, 13.61, 20.75, and 18.45, P=0.003, 0.005, 0.002, and 0.003). Luciferase reporter assay showed that compared with the NC group, miR-149, miR-490-5p, and miR-502-5p significantly reduced the activity of wild-type luciferase plasmids (t=10.01, 9.13, and 61.49, P=0.010, P=0.012, and P < 0.001). Conclusion Hsa_circ_0091579 is highly expressed in HCC cell lines and may play the role of oncogene by inhibiting miR-149, miR-490-5p, and miR-502-5p. -
Key words:
- Carcinoma, Hepatocellular /
- DNA, Circular /
- Cell Physiological Phenomena
-
图 2 hsa_circ_0091579 siRNA设计及沉默效率
注：a，hsa_circ_0091579 siRNA靶序列；b，qRT-PCR验证在HepG2和HuH-7细胞中转染降低hsa_circ_0091579。与NC组比较，*P < 0.05。
-
[1] CRAIG AJ, von FELDEN J, GARCIA-LEZANA T, et al. Tumour evolution in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(3): 139-152. DOI: 10.1038/s41575-019-0229-4. [2] CHEN F, FANG Y, ZHAO R, et al. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma[J]. Eur J Med Chem, 2019, 179: 916-935. DOI: 10.1016/j.ejmech.2019.06.070. [3] QIU M, XIA W, CHEN R, et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma[J]. Cancer Res, 2018, 78(11): 2839-2851. DOI: 10.1158/0008-5472.CAN-17-2808. [4] TAN S, GOU Q, PU W, et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer[J]. Cell Res, 2018, 28(6): 693-695. DOI: 10.1038/s41422-018-0033-7. [5] JECK WR, SHARPLESS NE. Detecting and characterizing circular RNAs[J]. Nat Biotechnol, 2014, 32(5): 453-461. DOI: 10.1038/nbt.2890. [6] MEMCZAK S, JENS M, ELEFSINIOTI A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency[J]. Nature, 2013, 495(7441): 333-338. DOI: 10.1038/nature11928. [7] TANG Q, HANN SS. Biological roles and mechanisms of circular RNA in human cancers[J]. Onco Targets Ther, 2020, 13: 2067-2092. DOI: 10.2147/OTT.S233672. [8] LI J, SUN D, PU W, et al. Circular RNAs in cancer: Biogenesis, function, and clinical significance[J]. Trends Cancer, 2020, 6(4): 319-336. DOI: 10.1016/j.trecan.2020.01.012. [9] HUANG A, ZHENG H, WU Z, et al. Circular RNA-protein interactions: Functions, mechanisms, and identification[J]. Theranostics, 2020, 10(8): 3503-3517. DOI: 10.7150/thno.42174. [10] HAN B, CHAO J, YAO H. Circular RNA and its mechanisms in disease: From the bench to the clinic[J]. Pharmacol Ther, 2018, 187: 31-44. DOI: 10.1016/j.pharmthera.2018.01.010. [11] ZHANG TR, HUANG WQ. Angiogenic circular RNAs: A new landscape in cardiovascular diseases[J]. Microvasc Res, 2020, 129: 103983. DOI: 10.1016/j.mvr.2020.103983. [12] XIONG DD, FENG ZB, LAI ZF, et al. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma[J]. Cell Death Dis, 2019, 10(9): 658. DOI: 10.1038/s41419-019-1890-9. [13] ZOU H, XU X, LUO L, et al. Hsa_circ_0101432 promotes the development of hepatocellular carcinoma (HCC) by adsorbing miR-1258 and miR-622[J]. Cell Cycle, 2019, 18(19): 2398-2413. DOI: 10.1080/15384101.2019.1618120. [14] WEI X, ZHENG W, TIAN P, et al. Oncogenic hsa_circ_0091581 promotes the malignancy of HCC cell through blocking miR-526b from degrading c-MYC mRNA[J]. Cell Cycle, 2020, 19(7): 817-824. DOI: 10.1080/15384101.2020.1731945. [15] ZHANG C, ZHANG C, LIN J, et al. Circular RNA hsa_circ_0091579 serves as a diagnostic and prognostic marker for hepatocellular carcinoma[J]. Cell Physiol Biochem, 2018, 51(1): 290-300. DOI: 10.1159/000495230. [16] ZUO Q, HE J, ZHANG S, et al. PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting Warburg effect by PPARγ-dependent WNT/β-catenin/pyruvate dehydrogenase kinase isozyme 1 axis[J]. Hepatology, 2021, 73(2): 644-660. DOI: 10.1002/hep.31280. [17] CHATURVEDI VK, SINGH A, DUBEY SK, et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma[J]. Microb Pathog, 2019, 128: 184-194. DOI: 10.1016/j.micpath.2019.01.004. [18] XIONG DD, DANG YW, LIN P, et al. A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma[J]. J Transl Med, 2018, 16(1): 220. DOI: 10.1186/s12967-018-1593-5. [19] O'BRIEN A, ZHOU T, TAN C, et al. Role of non-coding RNAs in the progression of liver cancer: Evidence from experimental models[J]. Cancers (Basel), 2019, 11(11): 1652. DOI: 10.3390/cancers11111652. [20] WEI L, WANG X, LV L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma[J]. Mol Cancer, 2019, 18(1): 147. DOI: 10.1186/s12943-019-1086-z. [21] QIU L, XU H, JI M, et al. Circular RNAs in hepatocellular carcinoma: Biomarkers, functions and mechanisms[J]. Life Sci, 2019, 231: 116660. DOI: 10.1016/j.lfs.2019.116660. [22] QIU LP, WU YH, YU XF, et al. The emerging role of circular RNAs in hepatocellular carcinoma[J]. J Cancer, 2018, 9(9): 1548-1559. DOI: 10.7150/jca.24566. [23] JIANG YL, SHANG MM, DONG SZ, et al. Abnormally expressed circular RNAs as novel non-invasive biomarkers for hepatocellular carcinoma: A meta-analysis[J]. World J Gastrointest Oncol, 2019, 11(10): 909-924. DOI: 10.4251/wjgo.v11.i10.909. [24] FU Y, CAI L, LEI X, et al. Circular RNA ABCB10 promotes hepatocellular carcinoma progression by increasing HMG20A expression by sponging miR-670-3p[J]. Cancer Cell Int, 2019, 19: 338. DOI: 10.1186/s12935-019-1055-z. [25] CHEN H, LIU S, LI M, et al. circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt/β-catenin pathway in hepatocellular carcinoma[J]. Onco Targets Ther, 2019, 12: 9539-9549. DOI: 10.2147/OTT.S229507. [26] GURIA A, SHARMA P, NATESAN S, et al. Circular RNAs-the road less traveled[J]. Front Mol Biosci, 2019, 6: 146. DOI: 10.3389/fmolb.2019.00146. [27] CHENG JL, LI DJ, LV MY, et al. LncRNA KCNQ1OT1 regulates the invasion and migration of hepatocellular carcinoma by acting on S1PR1 through miR-149[J]. Cancer Gene Ther, 2020. DOI:10.1038/s41417-020-0203-x. [Online ahead of print] [28] CHEN W, YE L, WEN D, et al. MiR-490-5p inhibits hepatocellular carcinoma cell proliferation, migration and invasion by directly regulating ROBO1[J]. Pathol Oncol Res, 2019, 25(1): 1-9. DOI: 10.1007/s12253-017-0305-4. [29] CHEN S, LI F, CHAI H, et al. miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma[J]. Biochem Biophys Res Commun, 2015, 464(2): 500-505. DOI: 10.1016/j.bbrc.2015.06.168. -
下载:
本文二维码
图(7)
计量
- 文章访问数: 1253
- HTML全文浏览量: 185
- PDF下载量: 55
- 被引次数: 0
